Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model

The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma

(2019) Lei Wang et al.   ONCOLOGY REPORTS

Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments

(2018) Jingping Hu et al.   CANCER LETTERS

Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model

(2018) Chulwon Kim et al.   CANCER LETTERS

Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways

(2018) Ali Dehghanifard et al.   Clinical Lymphoma Myeloma & Leukemia

Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention

(2018) Devesh Tewari et al.   PHARMACOLOGICAL RESEARCH

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies

(2018) Praful Ravi et al.   Blood Cancer Journal

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma

(2018) Muthu K. Shanmugam et al.   Frontiers in Pharmacology

Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells

(2018) Lian Liu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

(2018) Kerrie Faia et al.   PLoS One

Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation

(2018) Seiichi Okabe et al.   ANNALS OF HEMATOLOGY

Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB

(2018) Masanobu Tsubaki et al.   LABORATORY INVESTIGATION

2,5-Dihydroxyacetophenone Induces Apoptosis of Multiple Myeloma Cells by Regulating the MAPK Activation Pathway

(2017) Jeong-Hyeon Ko et al.   MOLECULES

Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN

(2017) Yiying Wu et al.   Food & Function

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

(2017) Craig T. Wallington-Beddoe et al.   Oncotarget

Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway

(2016) TOMOYA TAKEDA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Thromboxane A2Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (MAPK)-mediated G2/M Progression Delay and Cell Apoptosis

(2016) Qian Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

(2016) F Fan et al.   LEUKEMIA

NF-κB in cancer therapy

(2015) Feng Li et al.   ARCHIVES OF TOXICOLOGY

Analysis of the intricate relationship between chronic inflammation and cancer

(2015) Edna Zhi Pei Chai et al.   BIOCHEMICAL JOURNAL

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway

(2015) Jong Hyun Lee et al.   CANCER LETTERS

Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer

(2015) Kanjoormana A. Manu et al.   CANCER LETTERS

Formononetin inhibits enterovirus 71 replication by regulating COX- 2/PGE2 expression

(2015) Huiqiang Wang et al.   Virology Journal

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

(2015) Shikha Satendra Singh   WORLD JOURNAL OF GASTROENTEROLOGY

Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

(2015) Feng Li et al.   Oncotarget

γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model

(2015) Kodappully Sivaraman Siveen et al.   Oncotarget

Formononetin Promotes Cell Cycle Arrest via Downregulation of Akt/Cyclin D1/CDK4 in Human Prostate Cancer Cells

(2014) Tianyu Li et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

(2014) J Picot et al.   HEALTH TECHNOLOGY ASSESSMENT

Formononetin Inhibits Migration and Invasion of MDA-MB-231 and 4T1 Breast Cancer Cells by Suppressing MMP-2 and MMP-9 Through PI3K/AKT Signaling Pathways

(2014) R. Zhou et al.   HORMONE AND METABOLIC RESEARCH

Current treatment landscape for relapsed and/or refractory multiple myeloma

(2014) Meletios A. Dimopoulos et al.   Nature Reviews Clinical Oncology

Involvement of p38 MAPK in haemozoin-dependent MMP-9 enhancement in human monocytes

(2013) Amina Khadjavi et al.   CELL BIOCHEMISTRY AND FUNCTION

Selaginella tamariscina (Beauv.) possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signaling pathways

(2013) Jia-Sin Yang et al.   FOOD AND CHEMICAL TOXICOLOGY

Formononetin Inhibited the Inflammation of LPS-Induced Acute Lung Injury in Mice Associated with Induction of PPAR Gamma Expression

(2013) Zhanqiang Ma et al.   INFLAMMATION

Current Therapeutic Strategy for Multiple Myeloma

(2013) Kenshi Suzuki   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Neuroprotective Effects of Formononetin Against NMDA-Induced Apoptosis in Cortical Neurons

(2013) Zhen Tian et al.   PHYTOTHERAPY RESEARCH

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

(2013) C Chang-Yew Leow et al.   Blood Cancer Journal

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

First Evidence That  -Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF- B Pathway

(2012) K. A. Manu et al.   CLINICAL CANCER RESEARCH

Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft

(2012) KATHY KA-WAI AUYEUNG et al.   ONCOLOGY REPORTS

Multifaceted link between cancer and inflammation

(2011) Gautam Sethi et al.   BIOSCIENCE REPORTS

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells

(2011) Radhamani Kannaiyan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4

(2011) Kanjoormana Manu et al.   Molecular Cancer

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy

(2010) Feng Li et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Formononetin accelerates wound repair by the regulation of early growth response factor-1 transcription factor through the phosphorylation of the ERK and p38 MAPK pathways

(2010) Jeong-Eun Huh et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model

(2009) B. Sung et al.   MOLECULAR CANCER THERAPEUTICS

Potential pharmacological control of the NF-κB pathway

(2009) Gautam Sethi et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery?

(2008) David J. Newman   JOURNAL OF MEDICINAL CHEMISTRY